scientific journal | Q5633421 |
P6981 | ACNP journal ID | 71954 |
P8375 | Crossref journal ID | 2294 |
P8903 | HAL journal ID | 19713 |
P236 | ISSN | 0955-3886 |
1879-3126 | ||
P7363 | ISSN-L | 0955-3886 |
P1055 | NLM Unique ID | 9001514 |
P856 | official website | http://www.sciencedirect.com/science/journal/09553886 |
P10283 | OpenAlex ID | V8600569 |
P7662 | Scilit journal ID | 1808645 |
P1156 | Scopus source ID | 35768 |
P495 | country of origin | United Kingdom | Q145 |
P8875 | indexed in bibliographic review | Scopus | Q371467 |
P407 | language of work or name | English | Q1860 |
P123 | publisher | Pergamon Press | Q3375355 |
P1476 | title | Transfusion science |
Q73882623 | 12th Congress of the European Society of Apheresis. Abstracts |
Q48643431 | 1991 registry of the French Society of Hemapheresis (SFH): preliminary results for the first year of the on-line computer access file. The Registry Study Group |
Q126321861 | 5628727 Extracorporeal virioncidal apparatus |
Q77069319 | A case of idiopathic myelofibrosis with alloimmunization to HLA-identical platelet transfusions not responsive to antibody absorption over protein-A columns |
Q77052612 | A clinical and laboratory study of platelet concentrates produced by pooled buffy coat and single donor apheresis technologies |
Q77070705 | A co-ordinated IT system for the improved management of the blood supply |
Q77052581 | A comparison of in vitro storage markers between gamma-irradiated and non-irradiated apheresis platelet concentrates (APC) |
Q77052499 | A comparison of peripheral blood stem cell apheresis using the Fenwal CS3000 Plus and COBE Spectra |
Q33328379 | A contribution to the indications for platelet transfusion and determination of its therapeutic efficacy |
Q57110541 | A method for the cryopreservation of red blood cells using hydroxyethyl starch as a cryoprotectant |
Q45857360 | A multicentre prospective cohort study of immune function in patients treated with monoclonally immunopurified or resin-purified SNBTS high-potency factor VIII concentrate |
Q74107535 | A pilot study of large volume apheresis of red blood cells and plasma during one donation by allogeneic blood donors |
Q77129226 | A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome |
Q33573245 | A rational approach to regulation of gene therapy in Canada |
Q73252080 | A relationship between glucose metabolism and NO-mediated iron mobilization from cells |
Q44827651 | A risk-to-benefit analysis for central venous catheters |
Q33579189 | A survey of Canadian neonatal blood transfusion practices |
Q73689819 | A survey of autologous blood collection and transfusion in Japan in 1997 |
Q47333378 | A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis platelets |
Q77187713 | A workshop and symposium on haemopoietic stem cells. 16th April 1996 |
Q34062749 | Adoptive allogeneic immunotherapy--history and future perspectives |
Q74825524 | Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barré syndrome |
Q77157575 | Advantages of outsourcing the transfusion service |
Q33579630 | Altruism and payment in blood donation |
Q45750371 | An attempt to prepare hepatitis B virus (HBV)-free plasma by ultrafiltration using microporous regenerated cellulose hollow fiber |
Q77070696 | An overview of current opinions on automation in blood transfusion services |
Q33560556 | An overview of laboratory and clinical aspects of leucocyte-depleted blood components |
Q33571318 | Analysis of platelets by flow cytometry |
Q73126416 | Annexin V and platelet antigen expression is not altered during storage of platelet concentrates obtained with the AMICUS cell separator |
Q73565662 | Annexin V and platelet antigen expression is not altered during storage of platelet concentrates obtained with the AMICUS cell separator |
Q77139501 | Annexin V, a new marker of platelet storage lesion: correlation with dMPV |
Q45260543 | Anti-hepatitis C virus serology in patients affected with congenital coagulation defects: a comparative study using three second generation ELISA tests |
Q73565668 | Antifibrotic tendency as complement to inflammatory burnout? Six year IVIG treatment in a case with atherosclerosis and chronic hepatitis C |
Q74825538 | Apheresis activities in The Netherlands |
Q74828221 | Apheresis guidelines from the nurse/operator viewpoint |
Q77087943 | Application of DNA-based technology in blood transfusion |
Q33328383 | Application of therapeutic plasma exchange in hematology |
Q33571308 | Applications of flow cytometry in the analysis of blood leukocytes. |
Q33579626 | Are cytokines in platelet concentrates responsible for febrile transfusion reactions? |
Q59157811 | Are oral contraceptives removed during plasmapheresis? |
Q33571324 | Are there options for donor-derived i.m. anti-D IgG preparations other than to prevent Rh(D) sensitization? The intravenous route |
Q33562185 | Artificial blood substitutes |
Q33569381 | Aspects of platelet storage |
Q77157551 | Assessment of an instrument for automated reagent and specimen dispensing in blood banking |
Q61790142 | Assessment of disease activity in lupus |
Q30605437 | Assessment of perioperative blood transfusion in cardiac surgery using administrative data |
Q33881410 | Autoapheresis and intraoperative blood salvage in oncologic surgery |
Q77130341 | Autologous blood donation in cardiac patients |
Q33569412 | Autologous blood pre-deposit and cell salvage in orthopedic surgery |
Q114886807 | Autologous blood salvage during elective surgery |
Q33561328 | Autologous blood stem cell grafting in hematological malignancies. Present status and future directions |
Q33564440 | Autologous blood stem cell transplantation in myeloma |
Q73625014 | Automatic volumetric capillary cytometry in the routine of an apheresis unit involved in multicomponent collection |
Q77070716 | Automation in blood components processing: NLBTC perspective |
Q33571683 | Automation in quality assurance of blood components and the complementary role of audit |
Q64977144 | Automation in transfusion science. |
Q77070703 | Automation of mandatory testing of blood donations |
Q77070713 | Automation/computerization in blood processing |
Q77070699 | Automation/computerization in donor sessions |
Q33582620 | Availability of clotting factor concentrates in genetically engineered form |
Q64905044 | Bacterial contamination of cellular blood products: the Canadian perspective. |
Q33575830 | Biocompatibility in transfusion medicine |
Q33564428 | Biocompatibility of apheresis harness |
Q33577111 | Biocompatibility of extracorporeal circuits in heart surgery |
Q33564444 | Biocompatibility of extracorporeal immunoadsorption systems |
Q74824656 | Biocompatibility of leukocyte removal filters during bedside leukocyte filtration of red cell concentrates |
Q33867790 | Blood banking issues pertaining to neonatal red blood cell transfusions |
Q33328398 | Blood centres: the effect of cytokine therapy on transfusion medicine |
Q77052575 | Blood component irradiation and prevention of graft-versus-host disease |
Q43762849 | Blood transfusion and deep venous thrombosis in primary total hip and knee replacement surgery: a retrospective analysis of 339 patients |
Q33579382 | Blood transfusion in South Africa |
Q33867785 | Blood transfusion support in pediatric cardiovascular surgery. |
Q74828202 | Bone marrow processing on the Haemonetics V50 cell separator |
Q74828237 | Bone marrow transplantation using unrelated bone marrow donors--a technology in evolution |
Q33564459 | Bone marrow transplants for patients with acute leukemia and myelodysplastic syndrome using unrelated donors |
Q64963097 | Can (should) apheresis supplant whole blood collection? |
Q33332765 | Cascade filtration for TTP: an effective alternative to plasma exchange with cryodepleted plasma |
Q33569341 | Cellular and molecular mechanisms of graft-versus-host disease |
Q77820003 | Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components |
Q73689822 | Changes in the Canadian blood system: the Krever Inquiry, Canadian Blood Services and Héma-Québec. Krever Commission |
Q77110684 | Changes of haemorheological parameters when using plasma exchange, selective adsorption and membrane differential separation |
Q40681374 | Characterization and transfusion of in vitro cultivated hematopoietic progenitor cells |
Q77157595 | Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment |
Q33569833 | Clinical and laboratory aspects of TA-GVHD with reference to perinatal patients and gamma-irradiated red cell components |
Q33333390 | Clinical and laboratory factors that affect the post-transfusion platelet increment |
Q33559883 | Clinical application of functional assays for assessing the red cell antibody activity |
Q33930303 | Clinical application of therapeutic erythrocytapheresis (TEA). |
Q33328381 | Clinical applications of protein A immunoadsorption in thrombocytopenic disorders |
Q74824648 | Clinical applications of stem cell transfusion from cord blood |
Q34094824 | Clinical aspects of hemochromatosis |
Q33579647 | Clinical assessment and measurement of oxygen transport in the critical care setting |
Q30665601 | Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome |
Q33562171 | Clinical significance of renal biopsy in subacute lupus erythematosus |
Q33894603 | Clinical syndromes associated with cold agglutinins |
Q33584641 | Clinical use of recombinant FVIIa (rFVIIa). |
Q77141769 | Clinician's overview of platelet support |
Q77070733 | Cold activation of complement as a marker of hepatitis C viremia in sera from blood donors |
Q33564466 | Collection and transportation of human bone marrow cells from unrelated donors |
Q77110725 | Collection of peripheral blood stem cells (PBSC) after chemotherapy and administration of rhGM-CSF in children weighing less than 17 kg |
Q77110753 | Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation |
Q45750362 | Combining IgG and interferon alpha-2b in chronic hepatitis C virus infection |
Q73252059 | Combining iron chelators with the nucleoside analog didanosine in anti-HIV therapy |
Q77087938 | Comparative clinical studies of platelet concentrates: effects on clinical outcome and the use of healthcare resources. NBS Platelet Study Group |
Q74826035 | Comparison of four filters for leukocyte depletion of single donor plateletapheresis products |
Q77139494 | Comparison of performance of six different cell separators in collecting peripheral blood mononuclear cells |
Q33332144 | Comparison of platelet immunity in patients with SLE and with ITP. |
Q73252074 | Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications |
Q77051959 | Composition and immunoreactivity of serum low density lipoproteins (LDL) before and after LDL-apheresis on dextran sulfate-cellulose columns |
Q33584632 | Computer assisted prospective review of blood product utilization: a large hospital experience |
Q33584626 | Consensus conference on platelet transfusion. Final statement |
Q52466094 | Continuous flow cell separator use for bone marrow processing. |
Q33881416 | Corrective and preventive action |
Q73325655 | Cost containment in platelet transfusion: clinical and technical aspects |
Q73625028 | Cost effectiveness of quality assurance in plateletpheresis |
Q33559477 | Costing complexities in mixed apheresis |
Q77139467 | Cross-flow microfiltration of blood through an extracorporeal device: a study in parameterization |
Q33579171 | Current methods for the preparation of platelet concentrates: laboratory and clinical aspects |
Q73689861 | Current position on preparation and quality of leucodepleted platelet concentrates for clinical use |
Q74821879 | Current trends: evolving concepts in transfusion medicine. The need for standardization of cryoprecipitate-derived fibrin adhesive |
Q33571695 | Current trends: evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease |
Q33562178 | Current trends: evolving concepts in transfusion medicine. Leukoreduced blood components: "you can filter now or you can filter later.". |
Q41042650 | Current trends: evolving concepts in transfusion medicine: potential alternatives to platelet transfusion |
Q64389277 | Cyclosporin and plasmapheresis in treatment of progressive systemic lupus erythematosus (pSLE) |
Q74107507 | Cytokine accumulation in stored red cell concentrates: effect of buffy-coat removal and leucoreduction |
Q33569836 | Cytokines in platelet concentrates |
Q77137580 | Cytokines in platelet concentrates: a comparison of apheresis platelet (haemonetics) and filtered and unfiltered pooled buffy-coat derived platelet concentrates |
Q33579136 | Cytokines to reduce platelet transfusions: non-TPO cytokines |
Q126388730 | Cytokines to replace platelet transfusions |
Q77139478 | Decreasing blood donor exposure in the neonates by using dedicated donor transfusions |
Q33579423 | Dendritic cells: therapeutic potentials |
Q73252044 | Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy |
Q74107514 | Detection of nucleic acid sequences from bacterial species with molecular genetic methods |
Q77819999 | Developing effective working partnership with manufacturers |
Q77110762 | Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial |
Q77141788 | Differential reduction in lymphocyte and granulocyte content by removal of the buffy coat from fresh and overnight-stored blood. Comparison of manual and automated blood processing systems |
Q33334679 | Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine |
Q77497516 | Discontinuous automated calcium supplementation during thrombocytapheresis with the haemonetics MCS+ version C |
Q73689832 | Distribution of normal prion protein in blood |
Q73689874 | Does bacterial contamination of platelet concentrates influence the leucocyte content and the rate of platelet storage lesion? |
Q74829274 | Donor hemapheresis in France at the start of 1992 |
Q77052509 | Double-lumen inferior vena cava catheters for peripheral stem cell apheresis and transplantations |
Q53922996 | Dry platelets with the Dideco Excel apparatus. |
Q73086630 | Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield |
Q73835298 | Editorial |
Q93937549 | Editorial |
Q93944176 | Editorial |
Q93932867 | Editorial |
Q74107502 | Editorial: focus on quality assurance research development |
Q77052578 | Effect of 25 Gy gamma irradiation on storage stability of three types of platelet concentrates: a comparative analysis with paired controls and random preparations |
Q33569352 | Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors |
Q77087954 | Effect of cold storage on the haemostatic cascade systems |
Q74823899 | Effect of filtration, storage and platelet suspension media on platelet indices |
Q77819952 | Effect of intravenous immunoglobulin therapy on plasma complement |
Q77139485 | Effect of long-term platelet donation on lymphocyte subsets and plasma protein concentrations |
Q77137586 | Effect of pH and buffering condition on dMPV of three types of platelet concentrates |
Q77110712 | Effect of storage conditions on the CD34+ counts in flow cytometric analysis after anticoagulation of samples with EDTA |
Q74825306 | Effective concentration of bone marrow mononuclear cells using density gradient separation within an automated cell separator |
Q74828199 | Effectiveness of lymphocytapheresis in a patient with ankylosing spondylitis |
Q73329576 | Efficiency and safety of leukocyte filtration during cardiopulmonary bypass for cardiac surgery |
Q73252065 | Endocrine problems in ex-thalassemic patients |
Q77127079 | Enhancing the efficacy of preoperative autologous blood donation by erythropoietin |
Q33867803 | Establishment of new national proficiency testing schemes for leucodepleted blood components: UK. |
Q73689840 | Evaluating leucodepletion systems suitable for routine use |
Q30304029 | Evaluation of CAPTURE CMV solid phase testing over the allowable shelf-life of red blood cells (adenine-saline added). |
Q40769014 | Evaluation of Cobe Trima for the collection of blood components with particular reference to the in vitro characteristics of the red cell and platelet concentrates and the clinical responses to transfusion |
Q77141798 | Evaluation of a new 5-log filter or packed red cells leucodepletion |
Q77820021 | Evaluation of sampling procedures for quality monitoring of red cell concentrates: the need for improving sampling and sample handling techniques of red cell concentrate |
Q74823570 | Evaluation of the Fresenius cell separator AS 104 for harvesting peripheral blood stem cells in pediatric patients |
Q74828227 | Evaluation of the Organon Teknika Plasmapur system with new software and two types of filter |
Q33328387 | Evidence for proteolytic cleavage of covalently bound protein A from a silica based extracorporeal immunoadsorbent and lack of relationship to treatment effects |
Q33332147 | Ex vivo expansion of megakaryocytes |
Q123024452 | Experiments on enrichment of peripheral blood progenitor cells in an electric field |
Q77052604 | Exploiting temperature dependence to improve selectivity in membrane-based plasmapheresis |
Q74823891 | Extending the storage of red cells at 4 degrees C |
Q33573565 | Extracorporeal granulocytapheresis for cancer and rheumatoid arthritis |
Q33569398 | Extracorporeal photochemotherapy: a scientific overview |
Q33569404 | Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders |
Q33894607 | Factors influencing the outcome of leucodepletion system |
Q77110719 | Factors influencing the timing of peripheral blood stem cell collection (PBSC) |
Q28372927 | Falsely low calcium measurements after high volume plasma exchange in a patient with liver failure |
Q77087931 | Fibrin sealant: update on clinical studies |
Q61053604 | First results obtained in France with the latest model of the Fresenius cell separator: AS 104 |
Q73126424 | Flow cytometric analysis of platelet function in stored platelet concentrates |
Q77820025 | Flow cytometric determination of residual leucocytes in filter-depleted blood products: an evaluation of Becton-Dickinson's LeucoCOUNT system |
Q33571302 | Flow cytometry in the management of infection with human immunodeficiency virus |
Q38479592 | Flow cytometry related to hematopoietic malignancy |
Q33571314 | Flow cytometry related to red cells |
Q73252039 | Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1 |
Q77819956 | French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP) |
Q33328410 | Future directions in utilization review: the role of transfusion algorithms |
Q40930459 | Future trends for provision of safer blood components/blood products |
Q33579411 | Gene therapy for AIDS. |
Q33573235 | Gene therapy in Europe |
Q33573250 | Gene therapy with physical methods of gene transfer |
Q33579418 | Gene transfer into human haematopoietic stem cells |
Q33579429 | Graft T-cell depletion as a prerequisite for the modulation of alloreactivity after haematopoietic stem cell transplantation |
Q33569362 | Graft-versus-host disease and the development of late complications |
Q40883877 | Growth factors and thrombopoietin--impact on future patterns of platelet use. |
Q30321980 | HIV and blood transfusion in sub-Saharan Africa. |
Q60255539 | HIV-1 Detection and Subtyping by PCR and Heteroduplex Mobility Assay in Blood Donors: Can These Tests Help to Elucidate Conflicting Serological Results? |
Q73086637 | Haematopoietic stem cell transplantation |
Q73252077 | Haematopoietic stem cell transplantation for the management of haemoglobinopathies in Greek patients |
Q77110679 | Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment |
Q74828206 | Hazards of apheresis and the U.K. approach to guidelines |
Q41210072 | Hemapheresis and hemorheology |
Q77087969 | Hemapheresis listening post. Certification of the hemapheresis practitioner HP (ASCP) |
Q41012297 | Hemapheresis versus intravenous IgG: a debate for the 21st century |
Q77052590 | Hematopoietic engraftment from a minimal number of apheresis procedures after mobilization of peripheral blood stem cells with chemotherapy and rhG-CSF |
Q33579405 | Hematopoietic stem cell expansion |
Q77157558 | Hemorheology and therapeutic hemapheresis |
Q44951817 | Hepatitis B core antigen antibody as an indicator of a low grade carrier state for hepatitis B virus in a Saudi Arabian blood donor population |
Q42992857 | Hepatitis C virus RNA testing by nested PCR in blood preparations in Yugoslavia |
Q39172522 | Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission |
Q33575841 | How can we improve platelet preparation and storage? |
Q30658058 | Hydroxamate analog libraries and evaluation of their iron affinity |
Q73325644 | Hypercoagulability state in hip and knee surgery: influence of ABO antigenic system and allogenic transfusion |
Q77820029 | III-7 evaluation of IMAGN 2000: a new system for absolute leucocyte count |
Q30570471 | ISBT 128--a new international standard for labelling and data management in blood transfusion |
Q30571288 | IVBT-documented platelet function correlates with flow cytometric data |
Q73086648 | IVIG as a nonspecific accelerator of restitutio ad integrum |
Q74107530 | IgM alloantibody detection by M-MPHA, a new solid-phase assay system |
Q33569391 | Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases |
Q74821872 | Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992 |
Q77157589 | Immunoadsorption using the Excorim treatment system |
Q77157616 | Immunoadsorption--a new therapeutic possibility for multiple sclerosis? |
Q77157585 | Immunoglobulin and circulating immune complex kinetics during immunoadsorption onto protein A sepharose |
Q33581254 | Immunological effects of therapeutic immunoadsorption with respect to biocompatibility |
Q33579621 | Immunomodulation, autoimmunity and haemostatic dysfunctions |
Q77110696 | Immunosorbent for IgG apheresis: an in vitro study |
Q56932742 | Impact of autologous blood transfusion on blood support in general thoracic surgery: Analysis of 969 patients over a 5-year period |
Q77110758 | Improved lectin agglutination method for T-cell depletion of HLA-mismatched bone marrow grafts in children |
Q74825536 | Improvement of separation efficiency and concentrate purity of the Fresenius cell separator AS 104: results of a multicenter study. Haemapheresis Scientific Workshop Group of DGTI |
Q73882618 | Improvement of visual acuity in patients suffering from diabetic retinopathy after membrane differential filtration: a pilot study |
Q74821881 | In utero fetal liver cell transplantation in the treatment of immunodeficient or thalassemic human fetuses |
Q62090539 | In vitro analysis of platelet concentrates stored in the presence of modulators of 3′,5′ adenosine monophosphate, and organic anions |
Q74828231 | In vitro evaluation of a new dual screen microaggregate filter |
Q77157536 | In-process cell counts during preparation of platelet concentrates from buffy coats |
Q77137653 | Incidence of electrocardiographic changes during cytapheresis using an intermittent flow centrifuge, haemonetics V50 and a continuous flow centrifuge, AS104 |
Q73882614 | Increased anticoagulant osmolality improves separation of leukocytes from red blood cells (RBC) |
Q77172480 | Indications for a cost-saving policy in routine flow cytometry |
Q74825533 | Initial validation and quality control of platelet concentrates prepared by apheresis |
Q33575849 | Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs |
Q74828247 | Intensive plasmapheresis as an alternative therapy for intractable pruritus of primary biliary cirrhosis |
Q33579177 | International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience |
Q77069308 | International forum: France. The national survey of plasma exchange and therapeutic cytapheresis in France |
Q47715932 | International forum: Japan report on informed consent in blood transfusions |
Q45206452 | International forum: Saudi Arabia. Donor screening for HTLV-I in Saudi Arabia: is it cost effective? |
Q33571689 | International forum: Saudi Arabia. Peripheral blood stem cell harvest in Saudi Arabia. A review of the first decade |
Q77185707 | International forum: The U.K. A forum discussion on circles of dependence of quality in the blood transfusion community |
Q33579183 | International forum: U.K. Consensus conference on unrelated donor BMT: its use in leukaemias and allied disorders |
Q77819972 | International views on universal leucodepletion: the perspective in Germany |
Q95781295 | International views on universal leucodepletion: the perspective in NBS, England |
Q53345718 | International views on universal leucodepletion: the perspective in NBS, Ireland. |
Q52807129 | International views on universal leucodepletion: the perspective in Portugal. |
Q77819968 | International views on universal leucodepletion: the perspective in The Netherlands |
Q33578186 | Intraoperative hemodilution and autologous platelet rich plasma collection: two techniques for collecting fresh autologous blood |
Q33569407 | Intraoperative red cell retrieval in a multiple theatre programme |
Q33329015 | Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura |
Q33329019 | Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action |
Q73463326 | Is Brazil entering a new age? |
Q93948610 | Is Brazil entering a new age? |
Q74825302 | Italy and apheresis: a fresh look at the end of 1991 |
Q47224536 | L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients |
Q77069314 | LDL-apheresis in treatment of two patients with heterozygous familial hypercholesterolemia and extremely elevated lipoprotein (a) levels |
Q33559466 | LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia |
Q40783830 | LDL-apheresis: questions for the future |
Q73689859 | Laboratory and clinical aspects of platelet concentrates |
Q33579387 | Langerhans islet preparation in cell transplantation |
Q33573240 | Legal and ethical challenges in gene therapy |
Q33569386 | Leucocyte contamination of platelet products |
Q74825299 | Leucocyte depletion of neocyte-rich red blood cell concentrates by use of immunomagnetic beads |
Q53982535 | Leucocyte fragments in 'prestorage-leucodepleted' blood products: a qualitative analysis. |
Q73689851 | Leucodepletion and regulatory aspects in Germany |
Q73689842 | Leucodepletion monitoring by flow cytometry (Becton-Dickinson): from universal to statistical process monitoring |
Q34062739 | Leucodepletion process performance variation: is it dependent on the batch of filters, the processing centre or the counting technology? |
Q73689853 | Leucofiltration of sickle cell trait blood "the blocker": NBS London & S.E. experience |
Q73689857 | Leucofiltration, retention/generation of soluble prion and annexin V and storage of blood components |
Q74825526 | Leukocyte-depleted platelets prepared from pooled buffy coat post-transfusion increment and "in vitro bleeding time" using the Thrombostat 4000/2 |
Q77820012 | Leukocyte-poor platelet concentrates in routine production: preparation and cost |
Q77820009 | Leukodepleted blood components: definition of a standard |
Q77110690 | Lipoprotein(a)-apheresis in the secondary prevention of coronary heart disease |
Q77819995 | Logistical problems of supplying leucodepleted blood components within the national blood service |
Q73689865 | Lyophilized platelets: continued development |
Q33581244 | Making Landsteiner's discovery superfluous: safety and economic implications of a universal group O red blood cell supply |
Q33584646 | Mammalian recombinant coagulation proteins: structure and function |
Q33329011 | Management of children with acute and chronic immune thrombocytopenic purpura |
Q33329013 | Management of chronic autoimmune thrombocytopenic purpura (ITP) in adults |
Q33894599 | Management of cold agglutination syndrome |
Q33569357 | Management of graft-versus-host disease |
Q77157543 | Manual and automated methods for the determination of leukocyte counts at extreme low levels: comparative evaluation of the Nageotte chamber and the Abbott Cell Dyn 3500 analyser |
Q33328363 | Massive blood transfusion: the blood bank perspective |
Q74826032 | Membranes and polymer structures--biocompatibility aspects with respect to production limits |
Q33579166 | Methods for platelet preparation in Italy in 1996. |
Q33579399 | Methods of CD34+ cell separation: comparative analysis |
Q77052567 | Microchimerism after transfusion: the spectrum from GVHD to alloimmunization |
Q33573255 | Microencapsulation--an alternative approach to gene therapy |
Q77110677 | Modification of activation-dependent platelet antigens CD62p and CD63 during haemodialysis |
Q33569346 | Molecular and biological actions of cyclosporin A and FK506 on T cell development and function |
Q33573542 | Molecular biology of human immunodeficiency virus type-1. |
Q33894597 | Molecular characterization of cold agglutinins |
Q33579393 | Monocyte/macrophages as effector cells in cancer immunotherapy |
Q73252067 | Morbidity and mortality of iron intoxication in adult patients with thalassemia major, and effectiveness of chelation |
Q74825537 | Multicenter study of standardization of cell counting. Haemapheresis Scientific Workshop Group of DGTI |
Q73252055 | Multiple effects of iron chelators on molecules controlling cell cycle progression |
Q73126421 | Multiple red blood cell antibodies produced by donor B lymphocytes after ABO-matched allogeneic bone marrow transplantation |
Q43214430 | NBA/NBS perspective on nvCJD. |
Q77819989 | NBS approaches to the approval of suppliers of leucodepletion systems |
Q54472755 | National evaluation of IMAGN 2000 for quality monitoring of leucodepleted red cell and platelet concentrates: comparison with flow and Nageotte. |
Q50136000 | National survey of hemapheresis practice in Turkey (1998). |
Q33563055 | Neocyte transfusion: a current perspective |
Q74828250 | New "leap-frog" technique for autologous blood donation |
Q33565539 | New approaches for bone marrow purging |
Q40930464 | New horizons in blood transfusion medicine: present status and future trends |
Q74107525 | New plasma-reduced synthetic media, Fukushima cocktails, for the storage of platelets for transfusion |
Q33564433 | New strategies for plasma exchange in systemic vasculitis |
Q73252052 | Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia |
Q33328406 | Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). |
Q73325651 | Nutricel as an additive solution for neonatal transfusion |
Q33857225 | On the removal of diffusable substances from the circulating blood by means of dialysis. Transactions of the Association of American Physicians, 1913. |
Q74828217 | One American approach to apheresis guidelines |
Q77819985 | Operational and research approaches to universal leucodepletion in Scotland |
Q33565364 | Optimal venous access |
Q77110746 | PBSC collection from G-CSF primed donors |
Q42998818 | PCR testing for HCV in anti-HCV negative blood donors involved in the so called HCV +ve post-transfusion hepatitis |
Q33569759 | Perfluorochemical-based artificial oxygen carrying red cell substitutes |
Q33867781 | Perioperative autologous blood donation in children |
Q73325649 | Peripheral blood stem cell collection and transplantation using the Haemonetics Multi Component System |
Q73565665 | Peripheral blood stem cell collection and transplantation using the haemonetics multicomponent system |
Q77087961 | Peripheral blood stem cell collection from healthy donors for allogeneic transplantation |
Q34062744 | Peripheral blood stem cell collection: the interaction of technology, procedure, and biological factors |
Q74829269 | Peripheral blood stem cell transplantation for breast cancer patients with bone marrow metastases using GM-CSF priming |
Q33561324 | Peripheral blood stem cell transplantation: approaches to an optimal blood stem cell collection |
Q33569371 | Peripheral blood stem cell transplants in lymphoma |
Q40883890 | Perspective in platelet transfusion: current challenges and future trends |
Q40637987 | Perspective on Nordic views on selective/universal leukodepletion |
Q74821870 | Perspectives for apheresis in hypercholesterolaemia |
Q33561332 | Perspectives in marrow graft T-cell depletion in allogeneic matched related bone marrow transplantation |
Q33930298 | Pharmacological therapies to minimise platelet transfusion |
Q52083299 | Physical determinants of line pressures during apheresis. |
Q77070739 | Physico-chemical properties of membranes of recovered erythrocytes in blood autologous transfusion: a study using fluorescence technique |
Q33579635 | Physiology and pathophysiology of blood volume regulation |
Q77052587 | Pilot study of a new treatment concept for acute Guillain-Barré syndrome |
Q74825525 | Plasma exchange and selective adsorption in Guillain-Barré syndrome--a comparison of therapies by clinical course and side effects |
Q74830916 | Plasma exchange for Refsum's disease |
Q43713814 | Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience |
Q33562457 | Plasma exchange in Guillain-Barré syndrome and related disorders |
Q33573548 | Plasma exchange in chronic inflammatory demyelinating polyneuropathies |
Q33563051 | Plasma exchange: a potential role in promyelocytic leukemia--disseminated intravascular coagulopathy |
Q33857226 | Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. |
Q33584635 | Plasmapheresis in myasthenia gravis. A survey |
Q49116942 | Plasmapheresis--the Indiana connection |
Q127412678 | Platelet Depletion During Pediatric Peripheral Blood Progenitor Cell (PBPC) Harvesting |
Q33329005 | Platelet autoantibodies in immune thrombocytopenic purpura |
Q33329002 | Platelet cold agglutinins: a flow cytometric analysis |
Q60313669 | Platelet concentrates from buffy coats: Improved conditions for preparation and evaluation in routine clinical use |
Q33579161 | Platelet concentrates in Germany |
Q77087988 | Platelet loss during peripheral blood progenitor cell collections |
Q33579150 | Platelet production methods in the United Kingdom |
Q73689863 | Platelet products, where to? |
Q33560770 | Platelet storage in a liquid environment |
Q74826026 | Platelet storage lesions: analysis of platelet membrane glycoproteins and platelet-derived microparticles by fluorescence-activated flow cytometry |
Q33894594 | Platelet storage--1999 as good as it gets? |
Q40883884 | Platelet therapy: current opinions on laboratory and clinical aspects |
Q73625045 | Plateletapheresis: instrumentation validation |
Q33575835 | Plateletpheresis: what's new? |
Q33581221 | Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective |
Q77141781 | Possible implication of sterile connecting device in contamination of pooled platelet concentrates |
Q33335283 | Post-transfusion thrombocytopenia in recipients with anti-HLA antibody |
Q77141810 | Potential Creutzfeldt-Jakob disease (CJD) exposure: to notify or not to notify |
Q77819959 | Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components |
Q73625007 | Pre-separation storage of whole blood: the effect of temperature on red cell 2,3-diphosphoglycerate and myeloperoxidase in plasma |
Q74107546 | Pre-separation storage of whole blood: the effect of temperature on red cell 2,3-diphosphoglycerate and myeloperoxidase in plasma |
Q77052607 | Preclinical testing of lyophilized platelets as a product for transfusion medicine |
Q41738482 | Preliminary experience with plasma exchange in patients with ulcerative colitis |
Q33328403 | Prenatal determination of human platelet antigen type 4 by DNA amplification of amniotic fluid cells. |
Q73252030 | Preoperative autologous blood donation in hip surgeries |
Q74826029 | Preparation of random donor leukocyte-poor platelets by cytapheresis |
Q33560774 | Prestorage leukocyte reduction of cellular blood components |
Q44921713 | Prevention of infections transmissible by blood derivatives |
Q73252032 | Primary and secondary haemochromatosis |
Q30664845 | Principles of flow cytometry |
Q33583500 | Principles of risk management |
Q73689829 | Prions and blood transfusion |
Q33579155 | Production of platelet concentrates in Switzerland |
Q57390421 | Prospects of gene therapy for genetic skeletal muscle disease |
Q77157614 | Protein A immunoadsorption (i.a.) in renal transplantation patients with vascular rejection |
Q33328408 | Protein A immunoadsorption in alloimmunized patients refractory to platelet transfusions and in patients with treatment-resistant immune thrombocytopoenic purpura |
Q28373007 | Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome |
Q73325682 | Quality assurance in thrombapheresis |
Q73325686 | Quality assurance system in haemapheresis according to current good manufacturing practice |
Q74829272 | Quality control in stem cell processing for autotransplantation |
Q77141774 | Quality is a matter of mind: proposed quality improvement through the implementation of best practice |
Q33809954 | Quality monitoring of platelet concentrates: the need for standardization/harmonization of cellular content and assessment of platelet functional reserve |
Q33569841 | Quality of leukodepleted blood products |
Q33569375 | Quality of plasma for fractionation--does it matter? |
Q33581232 | Quality pays--in every business! |
Q73325658 | Quality, ISO 9002 and haemapheresis service |
Q73126412 | Quantitative PCR for counting residual white blood cells in blood products |
Q50243509 | Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood. |
Q45857366 | Recombinant factor VIIa (r-FVIIa) in haemophilia management |
Q33569764 | Recombinant growth factors |
Q77051948 | Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide |
Q33579660 | Red cell transfusion in specific circumstances |
Q33579656 | Red cell transfusion therapy in the critical care setting |
Q34094844 | Regulation of intracellular iron levels in iron-acceptor and iron-donor cells |
Q33569365 | Regulatory review of cellular and gene therapies: an overview of the process. |
Q33857281 | Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. |
Q73689834 | Removal of abnormal prion protein by plasma fractionation |
Q33573559 | Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood type incompatible couples |
Q73325689 | Results of an open, longitudinal multicenter LDL-apheresis trial |
Q77051964 | Results with new software for plateletpheresis systems |
Q38891109 | Revival of the Ugandan Blood Transfusion System 1989: an example of international cooperation |
Q73325663 | Rheological behaviour of red blood cells suspended in hemoglobin solutions. In vitro study comparing dextran-benzene-tetra-carboxylate hemoglobin, stroma free hemoglobin and plasma expanders |
Q74823560 | Risk management in transfusion medicine |
Q74823563 | Risk management in transfusion medicine: a hospital transfusion service perspective |
Q53667308 | Risk management in transfusion: an historical overview. |
Q33559471 | Role of LDL apheresis in the management of hypercholesterolaemia |
Q74825532 | Routine quality assurance requirements for apheresed platelets |
Q33573538 | Royal College of Physicians of Edinburgh Consensus Conference on autologous transfusion: final consensus statement |
Q77141760 | Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists consensus conference on anti-D prophylaxis 7-8 April 1997 |
Q77141794 | Satisfactory recovery and viability of stem cells cryopreserved at high cell concentration |
Q55242127 | Screening blood products for HTLV-I: what is the best approach? |
Q73689845 | Selective or universal leucodepletion: the Italian experience |
Q74822446 | Separation of buffy coat using the top and bottom drainage system: reduction of red blood cell loss |
Q77052622 | Shall red cell units stand upright, lie flat or be mixed during storage? In vitro studies of red cells collected in 0.5 CPD and stored in RAS2 (Erythrosol) |
Q77137641 | Should cardiac disease prevent autologous blood donation? |
Q33581209 | Should hospitals collect blood components? Yes: hospitals put patients first |
Q77157570 | Should hospitals collect blood components?: no |
Q73252026 | Single automated donor plateletpheresis increases the plasma level of proinflammatory cytokine tumor necrosis factor-alpha which does not associate with endothelial release markers von Willebrand factor and fibronectin |
Q33581227 | Single donor platelets: can we afford to use them? Can we afford not to use them? |
Q33565552 | Some principles of blood stem cell transplantation |
Q77070719 | Some ramblings on automation for a hospital blood transfusion laboratory |
Q33573553 | Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis |
Q74822435 | Standardization of plateletpheresis products |
Q33575845 | State of the art in platelet transfusion therapy |
Q77172457 | Statistical process validation of leucoreduced blood components |
Q77051981 | Stem cell procurement and transplantation in paediatric patients |
Q77110732 | Stem cell separation in paediatric patients |
Q74829259 | Stem cell transfusion |
Q33565533 | Stem cell transfusion from long-term marrow culture |
Q33565527 | Stem cells for grafting |
Q40879956 | Stem cells: what's happening? Current concepts and recent advances |
Q77201236 | Stem cells: what's happening? Focus on quality assurance, GMP and regulatory aspects |
Q95796665 | Stem cells: what's happening? Megakaryocyte growth and development factor and platelet aggregation |
Q77186543 | Stem cells: what's happening? Workshops and symposia on the subject of haematopoiesis |
Q74823896 | Storage of saline-adenine-glucose-mannitol suspended red cells in diethylhexyl phtalate and butyryl-n-trihexyl-citrate plasticized polyvinyl chloride containers. An in vitro comparative study |
Q77052594 | Studies on IgA class circulatory red cell antibodies--I. Preparation and identification of IgA class anti-A,anti-B |
Q77052598 | Studies on IgA class circulatory red cell antibodies--II. Properties of IgA class anti-A,anti-B |
Q77157566 | Successful prevention of posttransfusion hepatitis B by the combined use of immunoglobulin, vaccine and interferon |
Q44221603 | Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis |
Q45857377 | Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy |
Q60218216 | Symposium highlights: Future prospects for gene therapy |
Q77819930 | Symposium on Hemapheresis, international forum. Dordrecht, The Netherlands. Abstracts |
Q33582602 | Synchronization of plasma exchange and adjuvant treatments |
Q73689837 | Systematic RBC leucodepletion in France: where are we after six months? |
Q34062753 | T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999. |
Q77051994 | Technical and clinical experience with protein A immunoadsorption columns |
Q77110739 | Technical and safety aspects of blood and marrow transplantation using G-CSF mobilized family donors |
Q40879960 | The 90s paradox: QA efforts reduce total quality |
Q33569418 | The Allen Latham Award Lecture: specific immunotherapy for autoimmune disease |
Q33809949 | The Canadian Apheresis Group and therapeutic plasma exchange |
Q33329021 | The Canadian experience using plasma exchange for immune thrombocytopenic purpura. Canadian Apheresis Group |
Q74828214 | The French approach to donor apheresis guidelines |
Q74828213 | The French approach to therapeutic haemapheresis guidelines |
Q74828209 | The German approach to apheresis guidelines |
Q73689825 | The Second International Forum on variant CJD and leucodepletion: UK |
Q38495096 | The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). |
Q73625035 | The UK strategy for monitoring universal leucodepletion |
Q77087921 | The WAA next presidency--Genoa as a micro-image of apheresis evaluation over the next few years |
Q52542003 | The arguments for directed donations. |
Q41638064 | The biological significance and therapeutic potential of megakaryocyte growth and development factor (Mpl-ligand). |
Q33443420 | The blood bank and hepatitis G. |
Q33329007 | The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. |
Q52381192 | The clinician's approach to the management of risk. |
Q73882621 | The correlation between erythropoiesis and thrombopoiesis as an index for pre-operative autologous blood donation |
Q77087973 | The current status of extracorporeal immunomodulation |
Q34094832 | The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values |
Q73252082 | The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values |
Q33569769 | The development of hemoglobin solutions as red cell substitutes: hemoglobin solutions |
Q73252049 | The effect of deoxynucleosides on cell proliferation of peripheral blood lymphocytes treated with deferoxamine or hydroxyurea |
Q73329583 | The efficiency of PBPC collections and the relationship to the precollection concentration of CD 34+ cells in blood |
Q73625019 | The flow rate significantly influences the leukocyte depletion rate during prestorage in-line filtration of platelet concentrates |
Q74822439 | The growing practice of "splitting" double-dose apheresis platelet products |
Q31307005 | The history of idiopathic thrombocytopenic purpura (ITP). |
Q33579144 | The impact of peripheral blood stem cell transplants (PBSCT) on platelet usage |
Q73325675 | The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation |
Q34094818 | The importance of non-transferrin bound iron in disorders of iron metabolism |
Q77137627 | The influence of peri-operative blood transfusion during radical hysterectomy on the prognosis of uterine cervical cancer |
Q74825296 | The organization and operation of blood transfusion services in Andalusia |
Q33579641 | The physiology of oxygen transport |
Q73329579 | The platelet level indicates the erythropoietic capacity for preoperative autologous blood donation |
Q33564473 | The preparation of platelet concentrates by the light-spin/hard-spin technique |
Q33328358 | The problem of under utilization of therapeutic hemapheresis |
Q74829127 | The problem of vascular access for hemapheresis |
Q77137592 | The quality of clinical FFP, cryoprecipitate and cryosupernatant derived from single donor apheresis procedures and random donations collected in a BAT system: assessment of the activity states of FVIII, contact activation, microvesicle content and |
Q33582614 | The red blood cell utilization review experience |
Q33579652 | The red cell storage lesion and its implication for transfusion |
Q43214433 | The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion |
Q33569336 | The role of alloreactive cytotoxic and lymphokine-secreting T lymphocytes in the development of acute graft-versus-host disease |
Q33582595 | The role of flow cytometry in improving biocompatibility in transfusion medicine |
Q73835304 | The role of in process qualification in quality improvement of the haemonetics MCS plus leucodepleted platelet concentrate |
Q40920361 | The storage quality of apheresis platelets--analysis of results from seven different cell separators |
Q46656698 | The supply of blood products in 10 different systems or countries |
Q77820017 | The timing of leuko-depletion of apheresis platelets with a Sepacell PLS-5A filter does not affect glycoprotein IIb/IIIa-dependent platelet function in vitro |
Q33582608 | The transfusion audit as a tool to improve transfusion practice: a critical appraisal |
Q33582626 | The transfusion audit as an educational tool |
Q33581216 | The transfusion service is an integral and important component of the hospital and should not be outsourced |
Q77052601 | The use of therapeutic plasma exchange for treatment of acute polyradiculoneuropathy |
Q33564449 | The use of unrelated bone marrow transplantation in the treatment of chronic myelogenous leukemia |
Q33328414 | Therapeutic cytokine stimulation of thrombocytopoiesis |
Q33581248 | Therapeutic immunoadsorption--its role in clinical practice |
Q39513475 | Therapeutic leukapheresis |
Q33867776 | Therapeutic plasma exchange and cytapheresis in pediatric patients |
Q77157600 | Therapy of coagulation factor VIII autoantibodies with long-term extracorporeal protein A adsorption and immunosuppression |
Q40613541 | Three episodes of delayed hemolytic transfusion reactions due to multiple red cell antibodies, anti-Di, anti-Jk and anti-E. |
Q77137601 | Thrombopoietin |
Q33867797 | Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients |
Q33573262 | Transfusion practice in a Canadian hospital. Use of a major European study of transfusion practice for comparison as a form of audit |
Q33559876 | Transfusion support in liver transplantation |
Q33569828 | Transfusion-associated graft-versus-host disease (TA-GVHD): cellular mechanisms and their possible modulation by ultraviolet radiation |
Q33569846 | Transfusion-associated graft-versus-host disease: current concepts and future trends |
Q34094838 | Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). |
Q77123400 | Translumbar inferior vena cava catheters: experience with 58 catheters in peripheral stem cell collection and transplantation |
Q30321948 | Treatment of Guillain-Barré syndrome: listening carefully to the music before jumping on the bandwagon. |
Q77052018 | Treatment of Sézary syndrome with extracorporeal photochemotherapy |
Q33569394 | Treatment of autoimmune disease by immunomodulation through extracorporeal elimination and intravenous immunoglobulin |
Q73325672 | Treatment of chronic dysimmune polyneuropathies |
Q33583452 | Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Hemophilia Study Group |
Q77110702 | Treatment of graft versus host disease (GVHD) by photopheresis? |
Q74822448 | Treatment of homozygous familial hypercholesterolemia by plasma exchange and LDL-apheresis |
Q64972719 | Treatment of polyarteritis nodosa and Churg-Strauss syndrome: indications of plasma exchanges. |
Q77157606 | Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide |
Q33808870 | Treatment of the adult Guillain-Barré syndrome: indications for plasma exchange. |
Q77052584 | U.K. guidelines for the irradiation of blood components |
Q33930309 | UK strategy for process qualification/validation: from concept to practical implementation |
Q40650706 | Unexpected hemoglobin electrophoresis results following red cell exchange in a sickle cell anemia patient with acute chest syndrome |
Q77819976 | Universal leucodepletion--practical and regulatory consequences |
Q74828243 | Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies |
Q33564454 | Unrelated donor marrow transplantation for severe aplastic anaemia |
Q33648322 | Update on leucocyte depletion of blood components by filtration |
Q73252070 | Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases |
Q73625002 | Utility and quality of autologous fresh frozen plasma and autologous fibrin glue for surgical patients |
Q74107539 | Utility of red blood cell apheresis in autologous blood donation |
Q77819981 | Validation approaches selective/universal leucodepletion: the need for standardised validation strategies |
Q77819946 | Variation in weights of fresh frozen plasma |
Q74822442 | Viability of platelets collected by apheresis versus the platelet-rich plasma technique: a direct comparison |
Q33329009 | Virus-associated idiopathic thrombocytopenic purpura |
Q33761832 | What's happening? Cord blood derived stem cells: current views |
Q33940148 | What's happening? Current status of high dose chemotherapy in breast cancer |
Q33940153 | What's happening? Protein A columns: current concepts and recent advances |
Q77070724 | What's happening?: Stem cells. Current developments in haematopoietic progenitor cell transplantation |
Q33581238 | When less is more: cost-containment in transfusion medicine |
Q74107519 | White cell subsets in filtered red blood cell concentrates |
Q73689826 | nvCJD and leucodepletion: an overview |
Q34118818 | Standardization of B19 IgG ELISA to study the seroepidemiology of parvovirus B19 in North Indian voluntary blood donors | cites work | P2860 |
Search more.